[en] Most antidepressants are metabolized by cytochrome P450 (CYP) 2D6, and it is well known that there may be significant interindividual variation in the capacity to metabolize xenobiotics. About 7 to 10% of whites are poor metabolisers (PM), and, on the contrary, about 5% are ultrarapid metabolizers (UM), inducing very different rates in the transformation of antidepressants extensively metabolized by CYP 2D6. CYP 2D6 polymorphism can be a potential risk factor for the development of side effects or a reason for the poor efficacy of the treatment. Various probe drugs may be used for phenotyping CYP 2D6, but genotyping is now available using leukocyte DNA and is independent of concomitant drug use. in this study, we used PCR-based methods for the identification of CYP 2D6 genotypes in 49 patients receiving standard doses of fluoxetine or paroxetine and found that plasma concentration of the antidepressant drugs was significantly correlated with genetic status. In one patient who displayed CYP 2D6 gene duplication (UM), paroxetine plasma concentration was extremely low. in PM fluoxetine-treated patients, drug plasma concentration was significantly higher than that seen in extensive metabolizers.
Disciplines :
Pharmacie, pharmacologie & toxicologie
Auteur, co-auteur :
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Broly, Franck; CHRU Lille
Pinto, Emmanuel ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Plomteux, Guy ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Lhermitte, Michel; CHRU Lille
Langue du document :
Anglais
Titre :
Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine
Date de publication/diffusion :
décembre 2003
Titre du périodique :
Therapeutic Drug Monitoring
ISSN :
0163-4356
eISSN :
1536-3694
Maison d'édition :
Lippincott Williams & Wilkins, Philadelphia, Etats-Unis - Pennsylvanie
Steijns LS, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem. 1998;44:914-917.
Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P4502D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psych Scand Suppl. 1997;391:14-21.
Chen S, Wen-Hwei C, Blouin RA, et al. The CYP2D6 enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996;60:522-534.
Steimer W, Muller B, Leucht S, et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chimica Acta. 2001;308:33-41.
Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001; 104:173-192.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press, 1995.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:328-389.
Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol Clin Exp. 2000;15:453-459.
Skoda R, Gonzales FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA. 1988;85:5240-5243.
Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra rapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
Broly F, Marez D, Sabbagh N, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single stand conformation polymorphism analysis. Pharmacogenetics. 1995;5: 373-384.
Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193-202.
Rasmussen BB, Brosen K. Is TDM a case for optimising clinical outcome and avoiding interactions of SSRIs? Ther Drug Monit. 2000;22:143-154.
Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluxetine after multiple doses of fluoxetine in CYP2D6 poor and extensive metabolisers. J Clin Psychopharmacol. 2001;21:330-334.
Fjordside L, Jeppesen U, Eap CB, et al. The stereo-selective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9:55-60.
Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the SSRI paroxetine: nonlinearity and relation to the sparteine oxidation polyorphism. Clin Pharmacol Ther. 1992;51:288-295.
Montgomery SA, Kasper S. Side effects, dropouts from treatment and cost consequences. Int Clin Psychopharmacol. 1998;13(Suppl 2):1-5.
de Lean J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P4502D6 genotype in a psychiatric state hospital. Am J Psychiatry. 1998;155:1278-1280.
Reggiani K, Vandel P, Haffen E, et al. Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism. Encephale. 2000; 26:62-67.
Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573-585.
